Introduction/Background Ovarian cancer ranks as the second most prevalent gynaecological malignancy and is the primary cause of mortality among gynaecological cancers. The majority of women are diagnosed in advanced stages of evolution with limited chances of being cured. An effective strategy for treating epithelial ovarian cancer incorporates a comprehensive approach that includes surgical staging, cytoreduction, and platinum-based chemotherapy for suitable patients.

Methodology We present a case of a 37 years old patient, diagnosed with a voluminous bilateral ovarian tumor for which primary debulking surgery was performed in a multidisciplinary team. The evolution was uneventfull untill 6thpostoperative day when she developed convulsive seizures. Emergency cranian CT examination revealed a voluminous parasagittal frontoparietal brain lesion for which total tumor ablation was performed. Histopathological examination confirmed the serous papillary ovarian carcinoma as well as the fibroblastic atypical meningioma grade II. The patient was adressed to the oncology department where it was initiated adjuvant chemotherapy with Paclitaxel + Carboplatin protocol, in association with Bevacizumab. The patient has a favorable evolution following the treatment and no reccurences were noted 14 months after the initial diagnosis.

Results Although ovarian cancer is most commonly diagnosed by the gynaecologist, it is imperative that in advanced stages of evolution the management should be made in a multi-disciplinary team.

Conclusion We aimed to present a clinical case that we faced in our department to highlight the importance of a joint team in the proper management of advanced ovarian cancer. The conventional approach for treating ovarian cancer involves surgical intervention aimed at achieving total removal of the tumour, followed by chemotherapy use platinum compounds and taxanes. Establishing and recognizing the limitations of the gynaecologist can lead to clear protocols aimed at improving the approach to such a case.

Disclosures None.